Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

Veracyte announced that eight studies utilizing its Decipher Prostate Genomic Classifier test will be presented at the 2026 ASTRO Annual Meeting in Boston (September 26-30). The presentations include six oral presentations and two posters examining the test's prognostic and predictive value in assessing prostate cancer risk and identifying patients who may benefit from treatment intensification, including androgen-deprivation therapy combined with radiation.